BioCentury | Sep 19, 2016
Company News

GlaxoSmithKline, Aspen deal

...rights to marketed injectable anticoagulants Fraxiparine nadroparin, a low molecular weight heparin , and Arixtra fondaparinux...
BioCentury | Dec 11, 2014
Cover Story

Universal reversal for heparin

...partially effective against low molecular weight heparin (LMWH) therapies and not effective against the generic fondaparinux...
...$6.5 billion in global sales last year. 2,3 In contrast, global sales of UFH and fondaparinux...
...well under $1 billion. "The strength of protamine's binding interaction is not sufficient to neutralize fondaparinux...
BioCentury | Nov 20, 2014
Distillery Techniques

Technology: Drug platforms

...and biocompatibility assays, the lead reversal agent showed greater neutralization activity against the generic anticoagulant fondaparinux...
BioCentury | Sep 29, 2014
Company News

Aspen, Mylan deal

...rights to Arixtra fondaparinux and the authorized generic of Arixtra from Aspen. Mylan already sells Arixtra...
...interim distribution deal with Aspen, while Apotex Inc. (Toronto, Ontario) sells the authorized generic of Arixtra...
...sold the rights due to an absence of sales representatives in the U.S. Aspen acquired Arixtra...
BioCentury | May 19, 2014
Company News

Lee's Pharmaceutical, ScinoPharm Taiwan deal

...Lee's and ScinoPharm partnered to develop, produce and commercialize fondaparinux, travoprost and bimatoprost in China. Fondaparinux...
...rights to commercialize the products in China. Under the deal, ScinoPharm will provide API for fondaparinux...
...NYSE:AGN, Irvine, Calif.) markets bimatoprost as Lumigan to treat open-angle glaucoma and ocular hypertension. Fondaparinux...
BioCentury | Feb 27, 2014
Targets & Mechanisms

The XII factor

...Phase II Block coagulation Factor Xa Alchemia Ltd. (ASX:ACL); Dr. Reddy's Laboratories Ltd. (NYSE:RDY) Fondared fondaparinux...
...Marketed VTE Registration Atrial fibrillation (AF); stroke; DVT; PE; VTE GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Arixtra fondaparinux...
BioCentury | Oct 7, 2013
Company News

GlaxoSmithKline, Columbia University, New York University pharmaceuticals news

...syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI) who were initially treated with subcutaneous fondaparinux...
BioCentury | Oct 7, 2013
Company News

Aspen, GlaxoSmithKline, Merck sales and marketing update

...GlaxoSmithKline said it agreed to sell its injectable anticoagulants Fraxiparine nadroparin and Arixtra fondaparinux and the...
...products from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). Fraxiparine is low molecular weight heparin , and Arixtra...
BioCentury | Oct 2, 2013
Company News

No rejected requests under GSK transparency initiative

...syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI) who were initially treated with subcutaneous fondaparinux...
BioCentury | Jul 29, 2013
Company News

Aspen, GlaxoSmithKline deal

...branded and generic drug supplier Aspen offered to acquire injectable anticoagulants Fraxiparine nadroparin and Arixtra fondaparinux...
...products from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). Fraxiparine is low molecular weight heparin , and Arixtra...
...GSK reported £113 million ($171.9 million) in Fraxiparine sales and £94 million ($143 million) in Arixtra...
Items per page:
1 - 10 of 68